COMPASS THERAPEUTICS, INC. Revenue from Contract with Customer, Including Assessed Tax
COMPASS THERAPEUTICS, INC. (CMPX) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-03-05
- COMPASS THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $0.00.
- COMPASS THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $0.00.
- COMPASS THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- COMPASS THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for the quarter ending 2025-03-31 was $0.00.
- COMPASS THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2024 was $850.00K.
- COMPASS THERAPEUTICS, INC. revenue from contract with customer, including assessed tax for fiscal 2023 was $0.00.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $0.00 derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-05 | $850.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $850.00K derived: sum of 3 quarters · filed 2026-03-05 | $850.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $850.00K derived: sum of 2 quarters · filed 2025-11-05 | $850.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $850.00K 10-Q · filed 2025-08-11 | $850.00K 10-Q · filed 2025-08-11 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 derived: sum of 3 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |